ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.
ACM Biolabs has raised $6.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
ACM Biolabs's investors include Ritz Venture Capital.
ACM Biolabs is headquartered in Singapore, Singapore.
ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.
ACM Biolabs is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ACM Biolabs — Funding & Investors." VCBacked, September 22, 2022, https://www.vcbacked.co/company/acm-biolabs. Accessed November 13, 2026.
VCBacked. (2022). ACM Biolabs — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/acm-biolabs
{{cite web |title=ACM Biolabs — Funding & Investors |url=https://www.vcbacked.co/company/acm-biolabs |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ACM Biolabs? Request a listing update